Lonza, Agilent collaborate to integrate new analytical technologies

Lonza and Agilent Technologies have announced a collaboration that has the potential to transform the way personalised cell therapies are manufactured and realised. This collaboration will integrate Agilent’s current and new analytics technologies and techniques into the Lonza Cocoon Platform’s cell therapy manufacturing workflow to explore current and assess new Critical Quality Attributes (CQAs) required for the release of the therapeutic to the patient. By integrating Agilent analytical technologies both atline and in-line within the Cocoon Platform automated manufacturing workflows, manufacturers will be able to ensure that in-process controls and analytics can be employed on-demand to deliver a more consistent drug product. The Cocoon Platform is an automated and closed platform for patient-scale cell therapy manufacturing, designed to overcome manufacturing challenges associated with patient-scale personalised medicines.